First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer

HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer

https://ascopubs.org/doi/10.1200/JCO-25-02600

The HER2CLIMB study shows that the addition of Tucatinib to Trastuzumab and Pertuzumab maintenance after 4-8 cycles of THP induction prolongs PFS in 1st line HER-2 +. The benefit was present in both ER+ and ER- subsets.

The improvement of maintenance therapy gives people longer time off chemotherapy.

Tucatinib addition to Trastuzumab and Pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.